Biohaven And SK Biopharmaceuticals Enter Strategic Global Licensing Agreement; Stock Up
(RTTNews) – Biohaven Ltd. (BHVN) and SK Biopharmaceuticals Co., Ltd. announced a global licensing and collaboration agreement for Biohaven’s Kv7 ion channel platform, led by Opakalim (BHV-7000), a next-generation candidate in development for epilepsy. Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million, along with tiered royalties ranging…